Experience of effective antiviral therapy in a liver recipient with recurrent HCV infection genotype 1
https://doi.org/10.15825/1995-1191-2018-4-54-60
Abstract
HCV infection is one of the most common causes leading to the development of terminal liver diseases – cirrhosis and hepatocellular carcinoma, the main treatment for which is orthotopic liver transplantation. However, with continued virus replication, 100% reinfection occurs, which leads to the rapid progression of cirrhosis of the graft and the loss of its function. Standard interferon-containing therapy is ineffective for HCV infection, especially genotype 1, both before and after transplantation, and also has a wide range of adverse events. The article presents the successful experience of treating the recurrence of HCV infection 1 genotype in a patient who underwent liver transplantation and several courses of ineffective antiviral therapy.
About the Authors
D. V. Umrik
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
1, Shchukinskaya str., Moscow, 123182.
Tel. (926) 434-16-24.
O. M. Tsiroulnikova
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)
Russian Federation
Moscow
Russian Federation
Moscow
I. A. Miloserdov
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)
Russian Federation
Moscow
Russian Federation
Moscow
R. A. Latypov
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
E. T. Egorova
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Klempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.
2. Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010; 10: 1003–1019.
3. Roche B, Sebagh M, Canfora ML, Antonini T, RoqueAfonso A, Delvart V et al. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008; 14: 1766–1777. doi: 10.1002/lt.21635.
4. Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int. 2016 Sep; 10 (5): 749–761.
5. Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46: 459–465.
6. Watt K. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009; 9: 1707–1713.
7. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32: 673– 684.
8. Firpi RJ, Clark V, SoldevilaPico C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplantation. 2009; 15: 1063–1071.
9. European Liver Transplant Registry [Internet]. http://www.eltr.org/ Patient Survival vs Primary Indication. Available from: http://www.eltr.org/Overall-indication-and-results.html.
10. Zimmermann T, Bocher WO, Biesterfeld S et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007; 20: 583–590.
11. Jain A, Sharma R, Ryan C et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transpl. 2010; 24: 104–111.
12. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.
13. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6 (7): 1586–1599.
14. Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. American Health & Drug Benefits. 2015; 8: 142–147.
15. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), copackaged [prescribing information]. North Chicago, IL: AbbVie Inc; February 2015.
16. Kwo PY, Mantry PS, Coakley E et al. An interferonfree antiviral regimen for HCV after liver transplantation. The New England Journal of Medicine. 2014; 371: 2375–2382.
17. Yu ML, Chen YL, Huang CF et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.
18. Tronina O, Durlik M, Wawrzynowicz-Syczewska M et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/ PTV/r/+DSV±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Annals of Transplantation. 2017; 22: 199–207.
Review
For citations:
Umrik D.V., Tsiroulnikova O.M., Miloserdov I.A., Latypov R.A., Egorova E.T. Experience of effective antiviral therapy in a liver recipient with recurrent HCV infection genotype 1. Russian Journal of Transplantology and Artificial Organs. 2018;20(4):54-60. (In Russ.) https://doi.org/10.15825/1995-1191-2018-4-54-60
Views:
785
Email this article 